Rafael (NYSE:RFL) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) Compared

Which small-cap medical company is the better business?

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Rafael (NYSE:RFL) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but a comparison of the two businesses based on factors like earnings, profitability, analyst recommendations, valuation, risk, dividends, and institutional ownership suggests 60 Degrees Pharmaceuticals may be the more favorable stock.

Why it matters

This analysis provides insight into the relative strengths and weaknesses of these two small-cap pharmaceutical companies, which could be useful for investors looking to gain exposure to the medical sector.

The details

The key differences between the two companies include 60 Degrees Pharmaceuticals having stronger institutional ownership, higher earnings per share, and a higher potential upside according to analyst consensus. However, Rafael has lower share price volatility and a lower price-to-earnings ratio, making it potentially more affordable.

  • The analysis is based on data as of February 24, 2026.

The players

Rafael Holdings, Inc.

A holding company that engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.

60 Degrees Pharmaceuticals, Inc.

A specialty pharmaceutical company that develops and commercializes therapies for the prevention and treatment of infectious diseases in the United States.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the relative strengths and weaknesses of these two small-cap pharmaceutical companies, with 60 Degrees Pharmaceuticals appearing to have the edge in terms of analyst sentiment and growth potential, while Rafael may offer more affordability and stability. Investors should carefully consider their own investment goals and risk tolerance when evaluating these two stocks.